<p>Portage Biotech Inc. (NASDAQ:PRTG - 獲取免費報告) 在八月份的空頭頭寸顯著減少。截至 8 月 15 日，空頭頭寸總計為 7,200 股，較 7 月 31 日的 60,600 股減少了 88.1%。根據平均每日交易量為 881,800 股，目前的空頭頭寸比率為 0.0 天。公司股票約有 0.1% 被賣空。</p>
<p>獲取 <strong>Portage Biotech</strong> 警報：</p>
<h2>Portage Biotech 股價下跌 0.5%</h2>
<p>NASDAQ PRTG 股票在週二的午盤交易中下跌$0.03，報價$6.39。該股交易量為 834,279 股，相比平均交易量 356,332 股有所增加。公司的 50 天移動平均價為$3.70，200 天移動平均價為$6.65。該公司的市值為 1.1375 億美元，市盈率為-0.77，貝塔係數為 1.47。Portage Biotech 的 52 周最低價為$2.10，最高價為$61.99。</p>
<h2>關於 Portage Biotech（獲取免費報告）</h2>
<p>Portage Biotech Inc 是一家臨牀階段的免疫腫瘤學公司，從事製藥和生物技術產品的研究和開發。其產品管線包括：PORT-2 用於治療難治性非小細胞肺癌、黑色素瘤和難治性黑色素瘤，目前處於 I 期和 II 期臨牀試驗階段；PORT-3 用於治療實體腫瘤，目前處於 I 期臨牀試驗階段；PORT-6 是 A2AR 抑制劑，用於治療 A2A 和 A2B 高表達的實體腫瘤，目前處於 Ia 期臨牀試驗階段；PORT-7 是 A2AR 抑制劑，用於治療 A2A 和 A2B 高表達的實體腫瘤，目前處於 Ib 期臨牀試驗階段；PORT-1 是用於治療晚期軟組織肉瘤的腫瘤內溶脂溶液，目前處於 III 期臨牀試驗階段；PORT-4 是納米脂質凝膠聯合制劑，用於治療實體腫瘤，目前處於臨牀前試驗階段；PORT-5 是 VLP-STING，用於治療實體腫瘤，目前處於臨牀前試驗階段。</p>
<h2>精選文章</h2>
<ul>
<li>五支我們比 Portage Biotech 更看好的股票</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>研究：退休人員從兼職中賺取多少錢？</li>
<li>最佳 ESG 股票：ESG 投資的 11 支最佳股票</li>
<li>Brinker International 因 EPS 未達預期提供回調機會</li>
<li>什麼是 Euro STOXX 50 指數？</li>
<li>Globant 是新興的人工智能投資，正在擴大其影響力</li>
</ul>
<p><em>此即時新聞警報由敍事科技生成，使用 MarketBeat 的財務數據，旨在為讀者提供最快速和準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 預測拜登退出的人士：“準備迎接 “卡瑪拉崩盤”（來自 Paradigm Press）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5"/></p>
<h2>現在是否值得投資$1,000 在 Portage Biotech？</h2>
<p>在考慮 Portage Biotech 之前，您需要聽到這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户現在購買的股票清單...而 Portage Biotech 不在其中。</p>
<p>儘管 Portage Biotech 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
<p>查看這五支股票</p>

PRTG

ATON

<p>Portage Biotech Inc. (NASDAQ:PRTG) 在 8 月份空頭頭寸大幅減少了 88.1%，截至 8 月 15 日，空頭售出 7200 股，而 7 月 31 日為 60600 股。目前，該公司股票僅有 0.1% 被做空。平均每日交易量為 881,800 股，導致償還日比率為 0.0 天。儘管如此，PRTG 股票最近下跌了 0.5%，市值為 7500 萬美元，市盈率為-0.77</p>

<p>Portage Biotech Inc. (NASDAQ:PRTG - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 15th, there was short interest totalling 7,200 shares, a decrease of 88.1% from the July 31st total of 60,600 shares. Based on an average daily trading volume, of 881,800 shares, the short-interest ratio is currently 0.0 days. Approximately 0.1% of the company's stock are sold short.</p>
<div class="lb-trans"><p>Portage Biotech Inc. (NASDAQ:PRTG - 獲取免費報告) 在八月份的空頭頭寸顯著減少。截至 8 月 15 日，空頭頭寸總計為 7,200 股，較 7 月 31 日的 60,600 股減少了 88.1%。根據平均每日交易量為 881,800 股，目前的空頭頭寸比率為 0.0 天。公司股票約有 0.1% 被賣空。</p>
</div><p>Get <strong>Portage Biotech</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Portage Biotech</strong> 警報：</p>
</div><h2>Portage Biotech Stock Down 0.5 %</h2>
<div class="lb-trans"><h2>Portage Biotech 股價下跌 0.5%</h2>
</div><p>Shares of NASDAQ PRTG traded down $0.03 during midday trading on Tuesday, hitting $6.39. The stock had a trading volume of 834,279 shares, compared to its average volume of 356,332. The business's 50 day moving average is $3.70 and its 200-day moving average is $6.65. The company has a market cap of $113.75 million, a P/E ratio of -0.77 and a beta of 1.47. Portage Biotech has a 52 week low of $2.10 and a 52 week high of $61.99.</p>
<div class="lb-trans"><p>NASDAQ PRTG 股票在週二的午盤交易中下跌$0.03，報價$6.39。該股交易量為 834,279 股，相比平均交易量 356,332 股有所增加。公司的 50 天移動平均價為$3.70，200 天移動平均價為$6.65。該公司的市值為 1.1375 億美元，市盈率為-0.77，貝塔係數為 1.47。Portage Biotech 的 52 周最低價為$2.10，最高價為$61.99。</p>
</div><h2>About Portage Biotech (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Portage Biotech（獲取免費報告）</h2>
</div><p>Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A &amp; A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A &amp; A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.</p>
<div class="lb-trans"><p>Portage Biotech Inc 是一家臨牀階段的免疫腫瘤學公司，從事製藥和生物技術產品的研究和開發。其產品管線包括：PORT-2 用於治療難治性非小細胞肺癌、黑色素瘤和難治性黑色素瘤，目前處於 I 期和 II 期臨牀試驗階段；PORT-3 用於治療實體腫瘤，目前處於 I 期臨牀試驗階段；PORT-6 是 A2AR 抑制劑，用於治療 A2A 和 A2B 高表達的實體腫瘤，目前處於 Ia 期臨牀試驗階段；PORT-7 是 A2AR 抑制劑，用於治療 A2A 和 A2B 高表達的實體腫瘤，目前處於 Ib 期臨牀試驗階段；PORT-1 是用於治療晚期軟組織肉瘤的腫瘤內溶脂溶液，目前處於 III 期臨牀試驗階段；PORT-4 是納米脂質凝膠聯合制劑，用於治療實體腫瘤，目前處於臨牀前試驗階段；PORT-5 是 VLP-STING，用於治療實體腫瘤，目前處於臨牀前試驗階段。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Portage Biotech</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Study: How Much Are Retirees Earning from Side Hustles in 2024?</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>Brinker International Offers a Pullback Opportunity on EPS Miss</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Globant Is an Emerging AI Play That’s Expanding Its Footprint</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五支我們比 Portage Biotech 更看好的股票</li>
<li>對投資者最重要的沃倫·巴菲特股票：他自己的</li>
<li>研究：退休人員從兼職中賺取多少錢？</li>
<li>最佳 ESG 股票：ESG 投資的 11 支最佳股票</li>
<li>Brinker International 因 EPS 未達預期提供回調機會</li>
<li>什麼是 Euro STOXX 50 指數？</li>
<li>Globant 是新興的人工智能投資，正在擴大其影響力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科技生成，使用 MarketBeat 的財務數據，旨在為讀者提供最快速和準確的報道。本故事在發佈前已經經過 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Man who Predicted Biden’s Drop Out: “Prepare for “Kamala Crash” (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 預測拜登退出的人士：“準備迎接 “卡瑪拉崩盤”（來自 Paradigm Press）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzQ5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9349&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Portage Biotech right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資$1,000 在 Portage Biotech？</h2>
</div><p>Before you consider Portage Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Portage Biotech 之前，您需要聽到這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Portage Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五支頂級分析師悄悄告訴客户現在購買的股票清單...而 Portage Biotech 不在其中。</p>
</div><p>While Portage Biotech currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Portage Biotech 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五支股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五支股票</p>
</div>

Portage Biotech Inc.（納斯達克股票代碼：PRTG）的空頭頭寸減少了 88.1%